Navigation Links
Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Date:12/17/2008

SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced positive topline results from Study 304, a Phase III clinical trial of Acetavance(TM), the company's intravenous formulation of acetaminophen, for the treatment of acute pain following abdominal laparoscopic surgery. Study 304 successfully met its primary endpoint of a statistically significant reduction in summed pain intensity differences from baseline over 24 hours (SPID24) for Acetavance 1000 mg compared to placebo (p < 0.01).

Study 304 was a randomized, double-blind, multi-center study of 244 patients designed to evaluate the safety and efficacy of two dosing regimens of Acetavance, 1000 mg every six hours and 650 mg every four hours, compared to placebo over 24 hours. In addition to the 1000 mg dose administered every six hours meeting the primary endpoint, the trial also achieved a statistically significant reduction in SPID24 for the 650mg dose administered every four hours (p = 0.02). Consistent with other placebo-controlled clinical trials with intravenous acetaminophen, reported safety events from the Acetavance and placebo treated patients were similar. The company plans to communicate the full study results in a peer-reviewed venue.

Cadence also announced today that Study 351, a clinical trial evaluating the safety of repeated doses of Acetavance in adults, demonstrated a hepatic and general safety profile of Acetavance comparable to control (standard of care), with numerically lower proportions of subjects with elevated liver function tests in the two Acetavance groups compared to the standard of care group. Study 351 was an open-label, multi-center study of 213 hospitalized patients randomized to receive repeated doses of Acetavance 1000mg every six hours, Acetavance 650mg every four hours, or
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... ... has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It ... rapidly-growing alliance is dedicated to the provision of quality addiction treatment and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder and ... first in the area to offer RADIESSE® filler treatment for volume loss in the ... of tendons and veins in the hands, delivering smooth, natural-looking results that can last ...
(Date:9/1/2015)... IL (PRWEB) , ... September 01, 2015 , ... ... and Zeel™, has recently sponsored an educational workshop for physician assistants (PAs) practicing ... Injections of Traumeel™ and Zeel™” was held by Dr. Erick Salado, an orthopedic ...
(Date:9/1/2015)... ... September 01, 2015 , ... Curly Hair ... hair salons. This highly anticipated partnership between Curly Hair Solutions™ and Trade Secrets ... Founder Jonathan Torch and the Curly Hair Solutions™ team could not be more ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... released their latest predictive use case focused on helping hospital perform under the ... this program, hospital payments are adjusted based on performance across four domains related ...
Breaking Medicine News(10 mins):Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2
... , HOFFMAN ESTATES, Ill., July 16 ... America,s top medical institutions in the annual America,s Best Hospitals list published ... magazine. St. Alexius Medical Center was ranked among the top 50 hospitals ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090716/CG47487 ) ...
... NATICK, Mass., July 16 Boston Scientific Corporation (NYSE: ... from the U.S. Food and Drug Administration (FDA) to market ... drug-eluting stent (DES) designed for long lesions. At 38 ... option that can potentially reduce the number of stents used ...
... , PEKIN, Ill., July 16 ... of prescription foot and ankle orthoses and accompanying high technology ... award, which is given annually by the national Department of ... employment opportunities and support to veterans. , ...
... WALTHAM, Mass., July 16 According to Millennium ... intelligence, the fat reduction device market will experience the highest ... MRG,s European Markets for Body Contouring Devices 2009 ... fueled by physician adoption of newer modalities like transdermal ultrasound ...
... , , FRANKLIN, Mass., ... a company focused on innovative cardiac and vascular medical device-based ... Cardiac Angiography in Renally Impaired Patients (CARE) Study determined that ... from pulmonary edema to death, and that patients with CIN ...
... , , , BEIJING, July ... access to fast and efficient radiotherapy treatments with the introduction of ... ) at the Beijing Cancer Hospital. BCH is the first ... more advanced care to a greater number of patients. , ...
Cached Medicine News:Health News:St. Alexius Medical Center Named to America's Best Hospitals Rankings 2Health News:FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent 2Health News:FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent 3Health News:FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent 4Health News:PAL Health Technologies Wins State-Level Prestigious 'Employer of the Year' Award 2Health News:Fat Reduction Market in Europe to Soar Despite Economic Downturn 2Health News:PLC Medical Systems Announces Publication of Care Study Update 2Health News:PLC Medical Systems Announces Publication of Care Study Update 3Health News:Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 2Health News:Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 3
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today it has completed enrollment of ... Review Committee (DRC) earlier this year, into the ... a first-in-class innate defense regulator (IDR) and is ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... holística de l cuidado al paciente ... trayecto   Royal Philips  ... europeo de IntelliSpace Cardiovascular , un sistema web ... herramientas para acceder, analizar y compartir imágenes cardiovasculares e ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
... Caliper Life Sciences, Inc. (Nasdaq: ... and services for drug discovery and life sciences ... Austria AG for the co-development and manufacture of ... The agreement combines Sony DADC,s premier Blu-ray Disc™ ...
... Nov. 3, 2010 Cyberonics, Inc. (Nasdaq: CYBX ) ... second quarter ended October 29, 2010 of its fiscal year ending ... ET.  The company will conduct a conference call to discuss those ... Fiscal Year 2011 Second Quarter Results Conference Call InstructionsTo ...
Cached Medicine Technology:Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This instrument can be used as a spoon forceps in gynecologic surgery....
This is a single-action instrument that features a spring handle....
Medicine Products: